Overall Survival Results From Monaleesa-3 Study On Ribociclib Plus Fulvestrant In Advanced Breas...

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABC

Overall survival (OS) results of the Phase III MONALEESA-3 trial

Discussing the Latest Results From the MONALEESA-3 Study

Targeted Oncology

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-posi...

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast Cancer

MONARCH 2: Overall survival results from abermaciclib plus fulvestrant in HR+ HER2- advanced bre...

Practical Implications of the MONALEESA-3 Trial

Targeted Oncology

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...

CDK4/6 Inhibitor Maintained OS Benefit in Advanced Breast Cancer - Medpage Today

Potential in the MONALEESA-7 and MONALEESA-3 Trials

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

QOL in MONALEESA-2, 3, and 7

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic br...

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trial